Rivaroxaban Cuts Recurrent Blood Clots in Obese Patients
Patients on rivaroxaban also have lower health care resource utilization than those on warfarin (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 30, 2019 Category: Cancer & Oncology Tags: Cardiology, Family Medicine, Internal Medicine, Oncology, Pharmacy, Journal, Source Type: news
Rivaroxaban Cuts Recurrent Blood Clots in Obese Patients
MONDAY, Sept. 30, 2019 -- Real-world evidence shows that rivaroxaban reduces the risk for recurrent venous thromboembolism (VTE) in morbidly obese patients, with similar safety and efficacy as warfarin, according to a study published in the October... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 30, 2019 Category: Pharmaceuticals Source Type: news
Dying to be ill: Munchausen meets warfarin overdose - Akella P, Jindal V, Maradana S, Siddiqui AD.
Patients with severe coagulopathy related to vitamin K deficient proteins can be associated with surreptitious ingestion of vitamin K antagonists. Our patient presented acutely with extensive ecchymosis, gingival bleeding and hematuria. Her initial PT and ... (Source: SafetyLit)
Source: SafetyLit - September 28, 2019 Category: International Medicine & Public Health Tags: Poisoning Source Type: news
XARELTO ® (rivaroxaban) Reduces Recurrent Blood Clots and Total Medical Costs in Morbidly Obese Patients
New real-world study of patients with venous thromboembolism (VTE) and morbid obesity shows safety and effectiveness of XARELTO ® were similar to warfarin, with significantly less healthcare resource utilization (HRU) and total medical costs (Source: Johnson and Johnson)
Source: Johnson and Johnson - September 20, 2019 Category: Pharmaceuticals Source Type: news
Comparisons Between OACs Among Older Nonvalvular AF Patients Comparisons Between OACs Among Older Nonvalvular AF Patients
This study compared the risk of stroke and major bleeding with NOACs vs. warfarin among patients 80 years of age and older with nonvalvular atrial fibrillation.Journal of the American Geriatrics Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 13, 2019 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news
For Men, Living Alone May Mean Poorer Control of Blood-Thinning Meds
MONDAY, Sept. 2, 2019 -- Men who are on the blood-thinning drug warfarin have more difficulty taking the medication if they live alone, but the same is not true for women, a new study finds.
Warfarin (brand-name Coumadin) is a common anti-clotting... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 2, 2019 Category: General Medicine Source Type: news
Anniversary of the pivotal RE-LY ® trial marks a decade of innovation for stroke prevention in AF patients
Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, healthcare professionals (HCPs) and researchers.
In the fifty years prior, warfarin had been the standard of care for stroke prevention in atrial fibrillation (SPAF). (Source: World Pharma News)
Source: World Pharma News - August 30, 2019 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news
RE-LY-trial-publication-10-year-anniversary
Anniversary of the pivotal RE-LY ® trial marks a decade of innovation for stroke prevention in AF patients10 years ago, RE-LY ® marked the first time a randomised trial showed that a non-vitamin K antagonist oral anticoagulant (NOAC) was safer and at least as effective as warfarin for stroke prevention in atrial fibrillation (SPAF)1-3First major scientific advancement in anticoagulation care in over fifty yearsOver 100,000 patients have been included in the RE-VOLUTION study programme worldwide,4 and research into dabigatran etexilate continues (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 30, 2019 Category: Research Source Type: news
Docs Still in Dark on Anticoagulant Choice in Severe Kidney Disease Docs Still in Dark on Anticoagulant Choice in Severe Kidney Disease
Although NOACs offer"similar or greater benefit" over warfarin-like drugs in early chronic kidney disease, lack of evidence in severe disease makes anticoagulant choice a judgment call, say experts.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - July 15, 2019 Category: Neurology Tags: Nephrology News Source Type: news
History of Liver Disease Does Not Impact Efficacy of Edoxaban
TUESDAY, July 9, 2019 -- For patients with atrial fibrillation (AF), the efficacy and safety of edoxaban versus warfarin is not altered with a history of liver disease, according to a study published in the July 16 issue of the Journal of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 9, 2019 Category: Pharmaceuticals Source Type: news
Antithrombotic agents and traumatic brain injury in the elderly population: hemorrhage patterns and outcomes - Scotti P, S éguin C, Lo BWY, De Guise E, Troquet JM, Marcoux J.
OBJECTIVE: Among the elderly, use of antithrombotics (ATs), antiplatelets (APs; aspirin, clopidogrel), and/or anticoagulants (ACs; warfarin, direct oral ACs [DOACs; dabigatran, rivaroxaban, apixaban]) to prevent thromboembolic events must be carefully weig... (Source: SafetyLit)
Source: SafetyLit - July 8, 2019 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
DAPT for Preventing Thrombosis in Antiphospholipid Syndrome DAPT for Preventing Thrombosis in Antiphospholipid Syndrome
Can dual antiplatelet therapy effectively prevent thrombosis recurrence in patients with antiphospholipid syndrome? How does it compare to warfarin?Rheumatology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - July 4, 2019 Category: Allergy & Immunology Tags: Rheumatology Journal Article Source Type: news
Saving the Brain From Catheter Ablation of AF Saving the Brain From Catheter Ablation of AF
A new study examines when is it appropriate to stop DOACs before catheter ablation of AF. Does discontinuation hold the same peri-procedural risk of stroke as was seen with warfarin discontinuation?European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 26, 2019 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Plavix (clopidogrel) vs. Coumadin (warfarin)
Title: Plavix (clopidogrel) vs. Coumadin (warfarin)Category: MedicationsCreated: 6/25/2019 12:00:00 AMLast Editorial Review: 6/25/2019 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - June 25, 2019 Category: Cardiology Source Type: news
Study Refutes Notion That People on Warfarin Shouldn't Eat Leafy Greens
Title: Study Refutes Notion That People on Warfarin Shouldn't Eat Leafy GreensCategory: Health NewsCreated: 6/11/2019 12:00:00 AMLast Editorial Review: 6/12/2019 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - June 12, 2019 Category: Cardiology Source Type: news
